TANDEM DIABETES CARE INC 8-K

What Happened
Tandem Diabetes Care, Inc. filed an 8-K (Item 5.02) reporting that on May 11, 2026 the company notified Mark Novara, its Executive Vice President and Chief Commercial Officer, that his employment is being terminated without cause. Mr. Novara’s last scheduled day of employment is May 18, 2026. The filing, dated May 15, 2026, states the company’s strategy and 2026 goals remain unchanged.

Key Details

• Filing type: Form 8-K (Item 5.02 — Departure of Directors or Certain Officers).
• Notification date: May 11, 2026; last day of employment: May 18, 2026.
• Officer: Mark Novara, Executive Vice President & Chief Commercial Officer.
• Filing date/signature: 8-K filed May 15, 2026; signed by Shannon M. Hansen (EVP, Chief Legal, Privacy & Compliance Officer and Secretary).
• The filing does not name a successor and explicitly says the company’s strategy and 2026 goals remain unchanged.

Why It Matters
An executive departure at the chief commercial level can affect sales, commercial execution, and market-facing activities; the company’s disclosure is material information investors track under Item 5.02. Tandem has stated its strategy and 2026 goals are unchanged, but the filing did not identify a replacement—investors may want to watch for further disclosures about a successor or any changes to commercial leadership or guidance.